Comparison of Deferazirox and Deferoxamine on Serum Ferritin Levels Changes in Major Beta Thalassemia Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190817044550N4

Enrollment

Registered

2023-06-18

Start date

2022-10-23

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

beta thalassemia major. Beta thalassemia

Interventions

Intervention 1: Intervention group: Treated with deferasirox (Nanojade) ± Deferiprone. Intervention 2: Intervention group: Treated with deferoxamine (Desferal) ± deferiprone.

Eligibility

Sex/Gender

All

Age

2 Years to No maximum

Inclusion criteria

Inclusion criteria: The age of the patients was 2 years and older Have a normal serum creatinine level Absence of proteinuria in U/A patients The serum ferritin levels of the patients should be above 1000 mg/dl, or the patients should have had more than 10 blood transfusions, or the volume of blood transferred should be more than 100 cc/kg

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding Resistant levels greater than 5 times the normal value of liver transaminase Severe nausea and vomiting in the patient Patient refusal to participate in the study

Design outcomes

Primary

Measure	Time frame
Serum ferritin level. Timepoint: Measurement of serum ferritin level at the beginning of the study (before the start of the intervention), 3 and 6 months after the start of the intervention. Method of measurement: Biochemical test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeedeh Khorashadi zadeh

Birjand University of Medical Sciences

saedehkhorashadi4590@gmail.com+98 56 3162 2001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026